Option Care Health, Inc. (OPCH) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Option Care Health, Inc. operates as a single segment providing infusion therapy and ancillary healthcare services through a national network of 87 full-service pharmacies and 111 stand-alone ambulatory infusion suites. The company serves patients in home and non-hospital settings, contracting with managed care organizations, third-party payers, and hospitals.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Revenue | $1,350.7 million | $1,333.0 million |
| Gross Profit | $262.0 million | $263.1 million |
| Gross Margin | 19.4% | 19.7% |
| Operating Income | $72.5 million | $79.2 million |
| Net Income | $45.3 million | $46.7 million |
| Diluted EPS | $0.29 | $0.28 |
| Cash and Equivalents (End of Period) | $177.3 million | $171.4 million |
| Long-Term Debt (Net) | $1,153.0 million | $1,154.1 million |
| Available Liquidity (Revolver) | $846.0 million | $396.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 1.3% year-over-year, driven by high single-digit growth in the acute therapy portfolio. This was partially offset by a decline in the chronic portfolio due to patient attrition and unfavorable therapy mix in chronic inflammatory diseases (CID).
- Margin Compression: Gross margin decreased from 19.7% to 19.4%. Management attributes this to headwinds in the CID portfolio, which is now expected to negatively impact gross profit by approximately $55 million in 2026.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses rose 3.8% to $174.6 million due to investments in internal resources and technology. Depreciation and amortization decreased 5.3%.
- Cash Flow: Net cash used in operating activities increased to $12.1 million (from $7.2 million used in Q1 2025), primarily due to timing of vendor payments and higher accrued compensation payouts. Investing cash outflows decreased significantly as the prior year included a $117.2 million acquisition (Intramed Plus) with no comparable activity in Q1 2026.
- Debt Capacity: On March 30, 2026, the company amended its credit agreement to increase the Revolver Facility by $450 million, bringing total capacity to $850 million and available liquidity to $846 million.
Guidance, Outlook, and Risks
- Outlook: Management expects the CID portfolio dynamics to negatively impact gross profit by approximately $55 million in 2026. The company continues to invest in infrastructure and technology to support future growth.
- Capital Allocation: The company repurchased $17.5 million of common stock in Q1 2026. As of March 31, 2026, $675.0 million remains available under the share repurchase program.
- Risks: Key risks include reimbursement rate changes from government and commercial payers, patient attrition in chronic therapies, and the complexity of third-party billing arrangements. The company notes that the One Big Beautiful Bill Act (OBBBA) enacted in July 2025 has no material impact on the effective tax rate for this period.
- Contingencies: The company is involved in various legal proceedings and investigations typical of the healthcare industry but does not believe any pending matters will have a material adverse effect on financial statements.
Investor Verification Checklist
- CID Portfolio Impact: Verify the specific drivers of the $55 million projected gross profit headwind in the chronic inflammatory disease portfolio.
- Reimbursement Rates: Monitor payer mix shifts and potential changes in commercial and government reimbursement rates affecting net realizable value.
- Debt Covenants: Review the terms of the Fifth Amendment to the Credit Agreement regarding leverage ratios and interest rate exposure (SOFR + margin).
- Share Repurchase Pace: Assess the sustainability of the $675 million remaining repurchase authorization given current operating cash flow trends.
- Acquisition Strategy: Evaluate the pipeline for future "tuck-in" acquisitions given the significant increase in revolver capacity.